Anaplastic thyroid carcinoma (ATC) represents a rare yet highly malignant histotype of thyroid cancer. Cancer-associated fibroblasts (CAFs) play a pivotal role in tumor cell invasion, migration, and angiogenesis and present a potential target for cancer treatment. We aimed to investigate the effects of modulating specific subsets of CAFs on the proliferation, invasion, and migration of ATC.
Methods:
We developed nanosystems, platelet-derived growth factor receptor (PDGFR-β) targeted-polypeptide-modified poly (β-amino ester) (pBAE) (T-pBAE)/siB7-H3 nanoparticles (NPs), targeting PDGFR-β+ CAFs and featuring B7-H3 knockdown. We evaluated both the targeting efficacy and gene silencing performance of T-pBAE/siB7-H3 NPs, as well as the functional contribution of B7-H3 to CAFs-driven ATC progression.
Results:
T-pBAE/siB7-H3 NPs were efficiently internalized by CAFs, achieving targeted knockdown of B7-H3 expression. Silencing B7-H3 significantly suppressed the expression of cell division cycle 27 and other cell cycle-related genes, thereby inhibiting CAFs’ proliferation. Consequently, CAFs-secreted cytokines (e.g., CCL1 and CCL4) were altered. Through modulation of cytokine receptor activation on ATC cells, this process reduced ATC cell proliferation, invasion, and migration. In mice ATC subcutaneous tumor models, local injection of T-pBAE/siB7-H3 NPs reduced tumor volume. Moreover, the expression of invasive proliferation-related markers (PDGFR-β, Ki-67, CD31), immune evasion-related marker CD163, and chemoresistance-related marker ATP-binding cassette subfamily G member 2 was remarkably downregulated in tumor tissues.
Conclusion:
This study demonstrates that PDGFR-β polypeptide-modified pBAE could successfully deliver B7-H3 siRNA to CAFs. After knockdown of B7-H3 within CAFs, ATC proliferation, invasion, and migration were inhibited. Overall, our findings revealed that B7-H3 can be a promising therapeutic target for ATC.
Get full access to this article
View all access options for this article.
References
1.
DaviesL, WelchHG. Current thyroid cancer trends in the United States. JAMA Otolaryngol Head Neck Surg, 2014; 140(4):317–322; doi: 10.1001/jamaoto.2014.1
XuB, GhosseinRA. Advances in Thyroid Pathology: High Grade Follicular Cell-derived Thyroid Carcinoma and Anaplastic Thyroid Carcinoma. Adv Anat Pathol, 2023; 30(1):3–10; doi: 10.1097/pap.0000000000000380
4.
NagaiahG, HossainA, MooneyCJ, et al.Anaplastic thyroid cancer: A review of epidemiology, pathogenesis, and treatment. J Oncol, 2011; 2011:542358; doi: 10.1155/2011/542358
5.
SainiS, TullaK, MakerAV, et al.Therapeutic advances in anaplastic thyroid cancer: A current perspective. Mol Cancer, 2018; 17(1):154; doi: 10.1186/s12943-018-0903-0
6.
LuL, WangJR, HendersonYC, et al.Anaplastic transformation in thyroid cancer revealed by single-cell transcriptomics. J Clin Invest, 2023; 133(11):e169653; doi: 10.1172/jci169653
7.
PanZ, LiL, FangQ, et al.Integrated Bioinformatics Analysis of Master Regulators in Anaplastic Thyroid Carcinoma. Biomed Res Int, 2019; 2019:9734576; doi: 10.1155/2019/9734576
8.
ÖstmanA. Cancer-associated fibroblasts: Recent developments and emerging challenges. Semin Cancer Biol, 2014; 25:1–2; doi: 10.1016/j.semcancer.2014.02.004
9.
LangJ, ZhaoX, QiY, et al.Reshaping Prostate Tumor Microenvironment To Suppress Metastasis via Cancer-Associated Fibroblast Inactivation with Peptide-Assembly-Based Nanosystem. ACS Nano, 2019; 13(11):12357–12371; doi: 10.1021/acsnano.9b04857
10.
PanZ, XuT, BaoL, et al.CREB3L1 promotes tumor growth and metastasis of anaplastic thyroid carcinoma by remodeling the tumor microenvironment. Mol Cancer, 2022; 21(1):190; doi: 10.1186/s12943-022-01658-x
11.
MelisiD, Garcia-CarboneroR, MacarullaT, et al.TGFβ receptor inhibitor galunisertib is linked to inflammation- and remodeling-related proteins in patients with pancreatic cancer. Cancer Chemother Pharmacol, 2019; 83(5):975–991; doi: 10.1007/s00280-019-03807-4
12.
JohnsonDE, O’KeefeRA, GrandisJR. Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nat Rev Clin Oncol, 2018; 15(4):234–248; doi: 10.1038/nrclinonc.2018.8
13.
FozzattiL, ChengSY. Tumor Cells and Cancer-Associated Fibroblasts: A Synergistic Crosstalk to Promote Thyroid Cancer. Endocrinol Metab (Seoul), 2020; 35(4):673–680; doi: 10.3803/EnM.2020.401
14.
AbudukelimuS, de MirandaN, HawinkelsL. Fibroblasts in Orchestrating Colorectal Tumorigenesis and Progression. Cell Mol Gastroenterol Hepatol, 2024; 17(5):821–826; doi: 10.1016/j.jcmgh.2024.01.013
15.
LiW, LittleN, ParkJ, et al.Tumor-Associated Fibroblast-Targeting Nanoparticles for Enhancing Solid Tumor Therapy: Progress and Challenges. Mol Pharm, 2021; 18(8):2889–2905; doi: 10.1021/acs.molpharmaceut.1c00455
16.
PrakashJ. Cancer-Associated Fibroblasts: Perspectives in Cancer Therapy. Trends Cancer, 2016; 2(6):277–279; doi: 10.1016/j.trecan.2016.04.005
17.
VenningFA, ZornhagenKW, WullkopfL, et al.Deciphering the temporal heterogeneity of cancer-associated fibroblast subpopulations in breast cancer. J Exp Clin Cancer Res, 2021; 40(1):175; doi: 10.1186/s13046-021-01944-4
18.
ÖhlundD, ElyadaE, TuvesonD. Fibroblast heterogeneity in the cancer wound. J Exp Med, 2014; 211(8):1503–1523; doi: 10.1084/jem.20140692
19.
HuG, HuangL, ZhongK, et al.PDGFR-β(+) fibroblasts deteriorate survival in human solid tumors: A meta-analysis. Aging (Albany NY), 2021; 13(10):13693–13707; doi: 10.1863/2/aging.202952
20.
ChapovalAI, NiJ, LauJS, et al.B7-H3: A costimulatory molecule for T cell activation and IFN-gamma production. Nat Immunol, 2001; 2(3):269–274; doi: 10.1038/85339
21.
SeamanS, ZhuZ, SahaS, et al.Eradication of Tumors through Simultaneous Ablation of CD276/B7-H3-Positive Tumor Cells and Tumor Vasculature. Cancer Cell, 2017; 31(4):501–515; doi: 10.1016/j.ccell.2017.03.005
22.
SuhWK, GajewskaBU, OkadaH, et al.The B7 family member B7-H3 preferentially down-regulates T helper type 1-mediated immune responses. Nat Immunol, 2003; 4(9):899–906; doi: 10.1038/ni967
23.
GetuAA, TigabuA, ZhouM, et al.New frontiers in immune checkpoint B7-H3 (CD276) research and drug development. Mol Cancer, 2023; 22(1):43; doi: 10.1186/s12943-023-01751-9
24.
IngebrigtsenVA, BoyeK, NeslandJM, et al.B7-H3 expression in colorectal cancer: Associations with clinicopathological parameters and patient outcome. BMC Cancer, 2014; 14:602; doi: 10.1186/1471-2407-14-602
25.
UlaseD, BehrensHM, KrügerS, et al.Gastric Carcinomas with Stromal B7-H3 Expression Have Lower Intratumoural CD8+ T Cell Density. Int J Mol Sci, 2021; 22(4):2129; doi: 10.3390/ijms22042129
26.
ZongL, GuY, ZhouY, et al.Expression of B7 family checkpoint proteins in cervical cancer. Mod Pathol, 2022; 35(6):786–793; doi: 10.1038/s41379-021-00979-4
27.
ZhanS, LiuZ, ZhangM, et al.Overexpression of B7-H3 in α-SMA-Positive Fibroblasts Is Associated With Cancer Progression and Survival in Gastric Adenocarcinomas. Front Oncol, 2019; 9:1466; doi: 10.3389/fonc.2019.01466
28.
VentolaCL. Cancer Immunotherapy, Part 3: Challenges and Future Trends. P T, 2017; 42(8):514–521.
29.
ChengZ, FobianSF, GurrieriE, et al.Lipid-based nanosystems: The next generation of cancer immune therapy. J Hematol Oncol, 2024; 17(1):53; doi: 10.1186/s13045-024-01574-1
30.
ManiakasA, DaduR, BusaidyNL, et al.Evaluation of Overall Survival in Patients With Anaplastic Thyroid Carcinoma, 2000-2019. JAMA Oncol, 2020; 6(9):1397–1404; doi: 10.1001/jamaoncol.2020.3362
31.
BuchbinderEI, DesaiA. CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition. Am J Clin Oncol, 2016; 39(1):98–106; doi: 10.1097/coc.0000000000000239
32.
Arafat HossainM. A comprehensive review of immune checkpoint inhibitors for cancer treatment. Int Immunopharmacol, 2024; 143(Pt 2):113365; doi: 10.1016/j.intimp.2024.113365
33.
PaucekRD, BaltimoreD, LiG. The Cellular Immunotherapy Revolution: Arming the Immune System for Precision Therapy. Trends Immunol, 2019; 40(4):292–309; doi: 10.1016/j.it.2019.02.002
34.
DasS, JohnsonDB. Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. J Immunother Cancer, 2019; 7(1):306; doi: 10.1186/s40425-019-0805-8
35.
WangDY, SalemJE, CohenJV, et al.Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. JAMA Oncol, 2018; 4(12):1721–1728; doi: 10.1001/jamaoncol.2018.3923
36.
ChenS, SongZ, ZhangA. Small-Molecule Immuno-Oncology Therapy: Advances, Challenges and New Directions. Curr Top Med Chem, 2019; 19(3):180–185; doi: 10.2174/1568026619666190308131805
37.
BarataP, SoodAK, HongDS. RNA-targeted therapeutics in cancer clinical trials: Current status and future directions. Cancer Treat Rev, 2016; 50:35–47; doi: 10.1016/j.ctrv.2016.08.004
38.
FraireJC, HouthaeveG, LiuJ, et al.Vapor nanobubble is the more reliable photothermal mechanism for inducing endosomal escape of siRNA without disturbing cell homeostasis. J Control Release, 2020; 319:262–275; doi: 10.1016/j.jconrel.2019.12.050
39.
DoenchJG, PetersenCP, SharpPA. siRNAs can function as miRNAs. Genes Dev, 2003; 17(4):438–442; doi: 10.1101/gad.1064703
40.
HöijerI, EmmanouilidouA, ÖstlundR, et al.CRISPR-Cas9 induces large structural variants at on-target and off-target sites in vivo that segregate across generations. Nat Commun, 2022; 13(1):627; doi: 10.1038/s41467-022-28244-5
41.
ZhangXH, TeeLY, WangXG, et al.Off-target Effects in CRISPR/Cas9-mediated Genome Engineering. Mol Ther Nucleic Acids, 2015; 4(11):e264; doi: 10.1038/mtna.2015.37
42.
ShirleyJL, de JongYP, TerhorstC, et al.Immune Responses to Viral Gene Therapy Vectors. Mol Ther, 2020; 28(3):709–722; doi: 10.1016/j.ymthe.2020.01.001
43.
GhoshS, BrownAM, JenkinsC, et al.Viral Vector Systems for Gene Therapy: A Comprehensive Literature Review of Progress and Biosafety Challenges. Appl Biosaf, 2020; 25(1):7–18; doi: 10.1177/1535676019899502
44.
OoiYJ, HuangC, LauK, et al.Nontoxic, Biodegradable Hyperbranched Poly(β-amino ester)s for Efficient siRNA Delivery and Gene Silencing. ACS Appl Mater Interfaces, 2024; 16(11):14093–14112; doi: 10.1021/acsami.3c10620
45.
González-RíosN, ArtiguesM, Guerra-RebolloM, et al.Novel α-mannose-functionalized poly(β-amino ester) nanoparticles as mRNA vaccines with increased antigen presenting cell selectivity in the spleen. J Mater Chem B, 2023; 11(27):6412–6427; doi: 10.1039/d3tb00607g
46.
NicholsJW, BaeYH. EPR: Evidence and fallacy. J Control Release, 2014; 190:451–464; doi: 10.1016/j.jconrel.2014.03.057
47.
LiXY, HuSQ, XiaoL. The cancer-associated fibroblasts and drug resistance. Eur Rev Med Pharmacol Sci, 2015; 19(11):2112–2119.
48.
Yu-Wai-ManC, TagalakisAD, ManuntaMD, et al.Receptor-targeted liposome-peptide-siRNA nanoparticles represent an efficient delivery system for MRTF silencing in conjunctival fibrosis. Sci Rep, 2016; 6:21881; doi: 10.1038/srep21881
49.
TzengSY, HungBP, GraysonWL, et al.Cystamine-terminated poly(beta-amino ester)s for siRNA delivery to human mesenchymal stem cells and enhancement of osteogenic differentiation. Biomaterials, 2012; 33(32):8142–8151; doi: 10.1016/j.biomaterials.2012.07.036
50.
LeBleuVS, KalluriR. A peek into cancer-associated fibroblasts: Origins, functions and translational impact. Dis Model Mech, 2018; 11(4):dmm029447; doi: 10.1242/dmm.029447
51.
KalluriR. The biology and function of fibroblasts in cancer. Nat Rev Cancer, 2016; 16(9):582–598; doi: 10.1038/nrc.2016.73
52.
WangZ, WangZ, ZhangC, et al.Genetic and clinical characterization of B7-H3 (CD276) expression and epigenetic regulation in diffuse brain glioma. Cancer Sci, 2018; 109(9):2697–2705; doi: 10.1111/cas.13744
53.
RasicP, JeremicM, JeremicR, et al.Targeting B7-H3-A Novel Strategy for the Design of Anticancer Agents for Extracranial Pediatric Solid Tumors Treatment. Molecules, 2023; 28(8):3356; doi: 10.3390/molecules28083356
54.
SuS, ChenJ, YaoH, et al.CD10(+)GPR77(+) Cancer-Associated Fibroblasts Promote Cancer Formation and Chemoresistance by Sustaining Cancer Stemness. Cell, 2018; 172(4):841–856; doi: 10.1016/j.cell.2018.01.009
55.
WeiL, YeH, LiG, et al.Cancer-associated fibroblasts promote progression and gemcitabine resistance via the SDF-1/SATB-1 pathway in pancreatic cancer. Cell Death Dis, 2018; 9(11):1065; doi: 10.1038/s41419-018-1104-x
56.
YugawaK, YoshizumiT, ManoY, et al.Cancer-associated fibroblasts promote hepatocellular carcinoma progression through downregulation of exosomal miR-150-3p. Eur J Surg Oncol, 2021; 47(2):384–393; doi: 10.1016/j.ejso.2020.08.002
57.
YounesMN, KimS, YigitbasiOG, et al.Integrin-linked kinase is a potential therapeutic target for anaplastic thyroid cancer. Mol Cancer Ther, 2005; 4(8):1146–1156; doi: 10.1158/1535-7163.Mct-05-0078
58.
SerranoI, McDonaldPC, LockFE, et al.Role of the integrin-linked kinase (ILK)/Rictor complex in TGFβ-1-induced epithelial-mesenchymal transition (EMT). Oncogene, 2013; 32(1):50–60; doi: 10.1038/onc.2012.30
QueenA, BhuttoHN, YousufM, et al.Carbonic anhydrase IX: A tumor acidification switch in heterogeneity and chemokine regulation. Semin Cancer Biol, 2022; 86(Pt 3):899–913; doi: 10.1016/j.semcancer.2022.01.001
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
